Global Hemophilia B Market – Industry Trends and Forecast to 2029

Global Hemophilia B Market, By Drugs (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Others), Treatment (On-demand, Prophylaxis), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Hemophilia B Market Analysis and Size

The global hemophilia B market is expected to witness significant growth during the forecast period. Rising prevalence of rare disorders worldwide and emerging markets are the factors responsible for the growth of this market. The diagnosis of this disease is made by testing the blood for its capability to clot and its many levels of clotting factors. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of global hemophilia B market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global hemophilia B market in the forecast period 2022-2029. The expected CAGR of global hemophilia B market is tend to be around 9% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Haemophilia is a type of inherited, rare, genetic bleeding disorder in which the blood of the patient has insufficient levels of a clotting protein named as factor IX. It is caused due to the mutation in F9 gene on the X chromosome and is considered the second most common form of hemophilia.  

Hemophilia B Market Scope and Segmentation

Global Hemophilia B Market Dynamics

Drivers

• Increasing Incidence of Hemophilia

Haemophilia, a genetic bleeding disorder that stops the blood from clotting, is seen to typically affect 1 in 5,000 male births. According to the World Federation of Hemophilia, 184,723 people were affected with Hemophilia in 2016, along with 39,495 people with other bleeding disorders. This boosts the market growth.

Opportunities

• Advances in the Treatment Methods

Different treatment methods such as recombinant factor replacement therapy, which works as the first-line treatment for moderate to severe haemophilia patients, create opportunities for growth. Growing R&D investments and new drug launch in replacement therapy is projected to boost the segment's growth. Additionally, gene therapy is focused on identifying the defective DNA bases and then reinstating it with functional ones; this could provide good opportunities to present market players during the forecast period.  

• Increasing Demand for Retail Pharmacies

Rise in the number of drugs for hemophilia B being delivered through retail pharmacies and increase in the number of retail pharmacies in highly developed countries can create opportunities for the market growth. In addition to this, patients recommend retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Impending Drug Approvals

There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global hemophilia B market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hemophilia B market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hemophilia B Market               

COVID-19 has left a major global impact on industry growth during the forecast period. Transitions of healthcare infrastructure toward managing COVID-19 has led to several drug launch cancellations and delays in clinical trials. A number of research activities have been performed to understand the relation between the COVID-19 and haemophilia diseases. In addition to this, research has been performed in which researchers are trying to understand the correlation of mortality in patients due to the COVID-19 and haemophilia B.

In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the global haemophilia B market.

Global Hemophilia B Market Scope

The global hemophilia B market is segmented on the basis of drug, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Plasma Derived Coagulation Factor Concentrate
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Others

Treatment

• On-demand
• Prophylaxis

Route of Administration

• Oral
• Injectable

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hemophilia B Market Regional Analysis/Insights

The global hemophilia B market is analysed and market size insights and trends are provided by drug, treatment, distribution channel and end-user as referenced above.

The major countries covered in the global hemophilia B market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global hemophilia B market throughout the forecasted period due to increased patient awareness level as well as high prevalence of bleeding disorders.

North America dominates the market due to the high demand of diseases specific treatment, rise in adoption of newer technologies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hemophilia B Market Share Analysis

The global hemophilia B market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hemophilia B market.

Key players operating in the global hemophilia B market include:

• Gilead Sciences, Inc. (U.S.)
• Aspen Holdings (South Africa)
• Emcure Pharmaceuticals (India)
• Baxter (U.S.)
• Grifols S.A. (Spain)
• EMERGENT (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K)
• Bayer AG (Germany)